Shares of Dishman Carbogen Amcis rose 14% to Rs 124 on the BSE in intraday trade on Tuesday on heavy trading volume. In the past 11 trading sessions, the drugmaker’s share price has risen 51% from Rs 81.90 on February 6.

At 1:04 pm, Dishman was up 13% at Rs 122.95, while the S&P BSE Sensex was up 0.03%. A total of 6.44 million shares changed hands on the NSE and BSE, representing 4.1% of Dishman’s total share capital.

Dishman Carbogen Amcis is a fully integrated CRAMS (Contract Research and Manufacturing) company with strong capabilities from process development to late-stage clinical and commercial manufacturing and supply of APIs to innovative pharmaceutical companies.

The company operates globally, developing and manufacturing sites in Switzerland, the UK, France, the Netherlands, India and China.

Dishman offers end-to-end integrated high-value niche CRAMS products with a comprehensive product portfolio including APIs, high potency APIs, intermediates, phase transfer catalysts, vitamin D analogues, cholesterol and lanolin-related products, preservatives and sanitisers formulation.

Over the past year, however, the stock has fallen 31% compared with the S&P BSE Sensex’s 5% gain, underperforming the broader market. It has corrected 38% from its 52-week high of Rs 201 hit on April 5, 2022. It hit an all-time high of Rs 397 on January 25, 2018.

On February 13, 2023, Anvil Wealth Management Private Limited bought 1.19 million shares on the NSE at Rs 99.44 each, representing 0.76 per cent of Dishman’s total share capital, exchange data showed. The seller’s name was not immediately identified.

Meanwhile, for the October-December quarter (Q3FY23), Dishman reported a 32.7% year-on-year rise in its consolidated net profit to Rs 46.96 crore, compared to Rs 35.38 crore in Q3FY22. Net revenue rose 13.8% year-on-year to Rs 639.8 crore from Rs 562.08 crore in the year-ago period.

However, the EBITDA margin contracted to 18% in Q3FY23 compared to 19.5% in Q3FY22 due to lower EBITDA margins in India operations, especially the Bavla site, due to certain one-off EDQM Expenses and EBITDA margins in the Netherlands business were lower due to higher raw material prices and higher energy costs.